Apellis Pharmaceuticals Inc [APLS] stock prices are up 10.65% to $26.49 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares have gain 4.95% over the last week, with a monthly amount glided 12.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on October 15, 2025, and set its price target to $32. On September 26, 2025, downgrade downgraded it’s rating to Sell but maintained its price target of $18 on the stock. Raymond James downgraded its rating to an Outperform but stick to its price target of $52 on May 09, 2025. BofA Securities downgraded its rating to a Neutral but $23 remained the price target by the analyst firm on May 09, 2025. Cantor Fitzgerald started tracking with an Overweight rating for this stock on April 29, 2025, and assigned it a price target of $44. In a note dated December 17, 2024, Goldman downgraded a Neutral rating on this stock but restated the target price of $36.
The stock price of Apellis Pharmaceuticals Inc [APLS] has been fluctuating between $16.10 and $35.57 over the past year. Currently, Wall Street analysts expect the stock to reach $33.71 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $26.49 at the most recent close of the market. An investor can expect a potential return of 27.26% based on the average APLS price forecast.
Analyzing the APLS fundamentals
The Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 1.02B for trailing twelve months, representing a surge of 132.98%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.78 points at the first support level, and at 23.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.44, and for the 2nd resistance point, it is at 28.39.
Ratios To Look Out For
It’s worth pointing out that Apellis Pharmaceuticals Inc [NASDAQ:APLS]’s Current Ratio is 3.54. On the other hand, the Quick Ratio is 3.10, and the Cash Ratio is 1.71. Considering the valuation of this stock, the price to sales ratio is 3.30, the price to book ratio is 8.35 and price to earnings (TTM) ratio is 89.22.
Transactions by insiders
Recent insider trading involved Baumal Caroline, Chief Medical Officer, that happened on Jan 05 ’26 when 3020.0 shares were sold. Officer, Baumal Caroline completed a deal on Jan 05 ’26 to buy 3020.0 shares. Meanwhile, General Counsel Watson David O. sold 5000.0 shares on Dec 16 ’25.
